Finoriq research workspace
Alzamend Neuro, Inc. (ALZN) SEC Filings & Filing Highlights
Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline. Review ALZN SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
- Company
- Alzamend Neuro, Inc. (ALZN)
- Ticker
- ALZN
- Market Cap
- $4.8M
- Latest Price
- $1.26
- Industry
- Biotech & Pharma
Alzamend Neuro, Inc. (ALZN) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Alzamend Neuro, Inc. (ALZN).
| Event | Form | Date |
|---|---|---|
| Proposal One: The election of seven director nominees named by the Company to hold office until...On April 17, 2026, Alzamend Neuro, Inc., a Delaware corporation (the “Company”) held its annual meeting of stockholders (the “Annual Meetin... | 8-K5.07 | 2026-04-17 |
| Alzamend Neuro, Inc.: Exchange listing issueOn March 20, 2026, Alzamend Neuro, Inc., a Delaware corporation (the “Company”) received a letter (the “Letter”) from the Listing Qualifica... | 8-K3.01 | 2026-03-20 |
| The legal opinion of Olshan Frome Wolosky LLP, counsel to the Company, relating to the legality...On March 6, 2026, Alzamend Neuro, Inc. (the “Company”) entered into an At-the-Market Issuance Sales Agreement (the “Sales Agreement”) with... | 8-K1.01 | 2026-03-06 |
| Alzamend Neuro, Inc.: Corporate updateAlzamend Neuro, Inc., a Delaware corporation (the “Company”) has learned that Andrew H. Woo, M.D., Ph.D., a director of the Company, passed... | 8-K8.01 | 2025-11-18 |
| Amendments to Articles of Incorporation; Change in Fiscal YearAmendments to Articles of Incorporation; Change in Fiscal Year | 8-K5.03 | 2025-10-14 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.